Show simple item record

dc.contributor.authorZhao, Liangcai
dc.contributor.authorGao, Hongchang
dc.contributor.authorZhao, Yongxiang
dc.contributor.authorLin, Donghai
dc.contributor.author林东海
dc.date.accessioned2013-02-28T01:49:28Z
dc.date.available2013-02-28T01:49:28Z
dc.date.issued2012-08-01
dc.identifier.citationJOURNAL OF ETHNOPHARMACOLOGY,2012,142(3):647-656zh_CN
dc.identifier.issn0378-8741
dc.identifier.urihttp://dx.doi.org/10.1016/j.jep.2012.05.031
dc.identifier.uriWOS:000307035300007
dc.identifier.urihttps://dspace.xmu.edu.cn/handle/2288/14998
dc.description.abstractEthnopharmacological relevance: Zhibai Dihuang Pill (ZDP) is one of ancient traditional Chinese medicines (TCMs), which is usually used for the treatment of kidney deficiency for thousands of years in China. Aim of the study: Traditional Chinese medicines (TCMs) usually operate in vivo through multi-components, multi-ways and multi-targets. However, the molecular mechanisms of TCMs remain unclear. In the present work, nuclear magnetic resonance (NMR)-based metabonomic analysis was used to evaluate the therapeutic effect of Zhibai Dihuang Pill (ZDP) on diabetic nephropathy (DN) rats induced by streptozotocin and to address the underlying molecular mechanism. Materials and methods: Male rats were divided into three groups: control, DN and ZDP-treated DN (ZDP-DN), respectively. Based on H-1 NMR spectra of sera, urine and kidney extracts from the rats, principle component analysis (PCA) was performed to identify different metabolic profiles. Kidney portions and serum and urine samples were also subjected to histopathological or biochemical examination. Results: PCA scores plots demonstrate that the cluster of DN rats is separated from that of control rats, while some of ZDP-DN rats are located close to control rats, indicating that metabolic profiles of these ZDP-DN rats are restored toward those of control rats. Our results illustrate that ZDP treatment could lower the levels of lipids and 3-hydrobutyrate, and raise the level of lactate in sera of DN rats. Moreover, ZDP treatment could also reduce the levels of glucose, 3-hydrobutyrate and lactate, enhance the level of betaine in kidney tissues. Conclusion: Our study indicates that ZDP treatment can ameliorate DN symptoms by intervening in some dominating metabolic pathways, such as inhibiting glucose and lipid metabolism, enhancing methylamine metabolism. Our work may be of benefit to both evaluation of the therapeutic effect of TCM and elucidation of the underlying molecular mechanism. (C) 2012 Elsevier Ireland Ltd. All rights reserved.zh_CN
dc.description.sponsorshipNational Natural Science Foundation of China [81100598, 91129713, 31170717, 31000335]; Program of Shanghai Subject Chief Scientist [09XD1405100]zh_CN
dc.language.isoenzh_CN
dc.publisherELSEVIER IRELAND LTDzh_CN
dc.subjectMetabonomicszh_CN
dc.subjectNuclear magnetic resonancezh_CN
dc.subjectDiabetic nephropathyzh_CN
dc.subjectZhibai Dihuang Pillzh_CN
dc.titleMetabonomic analysis of the therapeutic effect of Zhibai Dihuang Pill in treatment of streptozotocin-induced diabetic nephropathyzh_CN
dc.typeArticlezh_CN


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record